Q3 FY22 Earnings Presentation
Key Product Approvals
Last 12 months: 200+ product approvals in key geographies¹
Gl Genius™
(U.S.)
Guardian™
Sensor
(EU)
4
UNiD™ Rods
(U.S.)
Vanta™ PC
Spinal Cord Stim
(U.S.)
SenSightTM
Directional
EvolutTM PRO+
TAVI System
Leads (EU)
(EU)
InPenTM
System
(EU)
SenSightTM
Directional Leads
(U.S.)
Q4 FY2021
Includes U.S., EU, Japan and China
Note: Relative positioning is not intended to signify relative timing
10 | Q3 FY22 earnings presentation | February 22, 2022
First line
indication for
Arctic Front™
(U.S.)
CoreValve™
Evolut™ FX
(U.S.)
Table of Executive Portfolio Financial Guidance &
Contents Summary Highlights Highlights Assumptions
NV Radial
Artery Access
Portfolio
(EU)
PillCam™
Small Bowel 3
@HOME
(U.S.)
Pill CENTI
CoreValve TM
Evolut™
PRO TAVR
(China)
Hugo™M
Robotic Assisted
Surgery Platform
(EU, AUS, CAN,
Israel)
Micra T
AV TPS
(Japan)
ESG Appendix
DPN indication
for Vanta Tr
& Intellis TM
(U.S.)
TM
Pediatric
Indication
Freezor™ &
Freezor™ Xtra
Cryoablation
Catheters
(U.S.)
|| 0 ||| Ở || 0 || TÔ ||||
Q3 FY2022
MedtronicView entire presentation